Latest Breaking News On - Arcutis biotherapeutics company profile - Page 4 : comparemela.com

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Receives $43 43 Consensus Price Target from Brokerages

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price […]

Arcutis biotherapeuticsArcutis biotherapeutics company profileNeedham companyWadegw incAlphacentric advisorsPrelude capital managementCantor fitzgeraldArcutis biotherapeutics incConnor clark lunn investment management ltdHennion walsh asset management incGoldman sachs groupGet free reportLunn investment managementCentric advisorsCapital managementWalsh asset management

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Receives Consensus Recommendation of Buy from Analysts

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report […]

Arcutis biotherapeuticsConnor clark lunn investment management ltdNeedham companyArcutis biotherapeutics incHennion walsh asset management incAlphacentric advisorsPrelude capital managementArcutis biotherapeutics company profileCantor fitzgeraldWadegw incGet free reportLunn investment managementCentric advisorsCapital managementWalsh asset managementGet free

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Given Consensus Rating of Buy by Analysts

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Given Consensus Rating of Buy by Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Arcutis biotherapeuticsJennison associatesCantor fitzgeraldArcutis biotherapeutics incBlackrock incArcutis biotherapeutics company profileGet free reportStreet corpCapital managementGet free

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Cut to $50 00 by Analysts at TD Cowen

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its target price reduced by TD Cowen from $65.00 to $50.00 in a research note issued to investors on Wednesday, Benzinga reports. TD Cowen currently has an outperform rating on the stock. A number of other brokerages also recently issued reports on ARQT. 500.com reaffirmed a reiterates rating […]

Arcutis biotherapeuticsMorgan stanleyJpmorgan chase coMetlife investment managementDimensional fund advisorsArcutis biotherapeutics company profileNeedham companyArcutis biotherapeutics incVanguard group incSwiss national bankFree reportGet free reportNational bankLife investment managementFund advisorsVanguard group

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 5 1%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s stock price fell 5.1% during mid-day trading on Monday . The company traded as low as $9.95 and last traded at $9.95. 147,462 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,102,637 shares. The stock had previously closed at […]

Hong kongArcutis biotherapeuticsZurcher kantonalbank zurich cantonalbankArcutis biotherapeutics incArcutis biotherapeutics company profileFirst republic investment management incNeedham companyBallentine partnersHong kong ltdGet free reportKong ltdKantonalbank zurich cantonalbankRepublic investment managementNasdaq arqt